BUSINESS
Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
MSD’s COVID-19 pill Lagevrio (molnupiravir) was included in the Japanese NHI price list on August 18, opening the way for its distribution through normal channels, the company said. The drug maker did not disclose when…

LATEST

August 19, 2022
Astellas Pharma said on August 18 that the US FDA has accepted for review its nonhormonal agent fezolinetant for the treatment of vasomotor symptoms (VMS) associated with menopause, known as hot flashes or night sweats.The…
August 19, 2022
Mochida Pharmaceutical said on August 18 that a new once-daily soft capsule version of its hyperlipidemia drug Epadel (ethyl icosapentate) listed the same day will be available on September 12.The new product, Epadel EM Capsules 2 g, is a self-emulsifying…
August 18, 2022
Forxiga (dapagliflozin) became the top-selling diabetes drug in Japan in April-June, according to data released by IQVIA on August 17. The SGLT2 inhibitor snapped the winning streak of the DPP-4 inhibitor Januvia (sitagliptin) for the…
By Eric Persoff

There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…

By Izuru Ando

Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA